Skip to main content Back to Top
Advertisement

8/21/2020

Eptifibatide Injection

Products Affected - Description

    • Integrilin injection, Merck, 2 mg/mL, 100 mL vial, 1 count, NDC 00085-1177-02
    • Eptifibatide injection, Akorn, 0.75 mg/mL, 100 mL vial, 1 count, NDC 17478-0903-90
    • Eptifibatide injection, Akorn, 2 mg/mL, 10 mL vial, 1 count, NDC 17478-0902-10
    • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
    • Eptifibatide injection, AuroMedics, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99

Reason for the Shortage

    • Accord has temporarily discontinued eptifibatide injection.
    • Akorn is not currently marketing eptifibatide.
    • Amneal did not provide a reason for the shortage.
    • Auromedics did not provide a reason for the shortage.
    • Baxter has eptifibatide injection available.
    • Merck did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage.
    • Sagent states the shortage is due to manufacturing delay.
    • Slate Run has eptifibatide injection available.

Available Products

    • Integrilin injection, Merck, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00085-1136-01
    • Integrilin injection, Merck, 2 mg/mL, 10 mL vial, 1 count, NDC 00085-1177-01
    • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
    • Eptifibatide injection, AuroMedics, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
    • Eptifibatide injection, AuroMedics, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
    • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
    • Eptifibatide injection, Mylan Institutional, 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
    • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
    • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
    • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
    • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10
    • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
    • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80

Estimated Resupply Dates

    • Amneal has eptifibatide 0.75 mg/mL in 100 mL vials on back order and the company cannot estimate a release date.
    • Auromedics has eptifibatide 2 mg/mL in 100 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Merck has Integrilin 2 mg/mL in 100 mL vials on back order and the company cannot estimate a release date.

Updated

Updated August 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.